Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a world-wide projection. Osteoporosis Int 1992;2:285–9.
Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M. HRT: an analysis of benefits, risks and costs. Br Med Bull 1992;48:368–400.
Cheung AP, Wren BG. A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 1992;156:312–6.
Weinstein MC. Oestrogen use in postmenopausal women: costs, risks, and benefits. N Engl J Med 1980;303:308–16.
Weinstein MC, Tosteson ANA. Cost-effectiveness of hormone replacement. Ann NY Acad Sci 1990;592:162–72.
Reid IR. Benefits, risks and costs of calcium supplementation in postmenopausal women. PharmacoEconomics 1994;5:1–4.
Johnell O. Prevention of fractures in elderly: a review. Acta Orthop Scand 1995;66:90–8.
Ribot C, Tremollieres F, Pouilles JM, et al. Risk factors or hip fracture. MEDOS study: results of the Toulouse Centre. Bone 1993;14:S77–80.
Aloia JF, Cohn SH, Vaswani A, Yeh JK, Yuen K, Ellis K. Risk factors for post-menopausal osteoporosis. Am J Med 1985;78:95–100.
Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ 1986;5:1–30.
Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1989.
Mooney G. Economics, medicine and health care. Brighton: Wheatsheaf Books, 1986.
Weinstein MC. Principles of cost-effective resource allocation in health care organizations. Int J Tech Ass Health Care 1990;6:93–103.
Cairns J. Discounting and health benefits: another perspective. Health Econ 1992;1:76–9.
Parsonage M, Neuburger H. Discounting and health benefits. Health Econ 1992;1:71–6.
Winner SJ, Morgan CA, Evans JG. Perimenopausal risk of falling and incidence of distal forearm fracture. BMJ 1989;298:1486–8.
Melton LJ, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol 1989;129:1000–11.
Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 1992;7:221–7.
WHO. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis (WHO technical report series 843). Geneva: WHO, 1994.
Overgaard K, Hansen MA, Birk Jensen S, Christiansen C. Effects of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556–61.
Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992;305:1124–8.
Watts NB. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73–9.
Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37.
Delva MD. Hormone replacement therapy: risks, benefits, and costs. Can Fam Physician 1993;39:2149–54.
Whittington R, Faulds D. Hormone replacement therapy. II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease. PharmacoEconomics 1994;5:513–54.
Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062–1071.
Jacobs HS, Loeffler FE. Postmenopausal hormone replacement therapy. BMJ 1992;305:1403–8.
Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal oestrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141–6.
Barrett-Connor E, Buch TL. Oestrogen and coronary heart disease in women. JAMA 1991;265:1861–7.
Stamper MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal oestrogen therapy and coronary heart disease. Engl J Med 1985;313:1044–9.
Stamper MJ, Colditz GA, Willett WC, et al. Postmenopausal oestrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756–62.
Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988;42:832–8.
Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after oestrogen and oestrogen-progestin replacement. N Engl J Med 1989;321:293–7.
Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of oestrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985–90.
Chapuy MC, Arlott ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1627–42.
Ankjaer-Jensen A, Thune Jacobsen E, Smidt Thomsen I. Rehabilitering af aeldre med hoftebrud: Omkostninger og effekt (DSI-rapport 94.08). Copenhagen: Dansk Sygehus Institut, 1994.
Nevitt MC, Johnell O, Black DM, Ensrud K, Genant HK, Cummings SR. Bone mineral density predicts non-spine fractures in very elderly women. Osteoporosis Int 1994;4:325–31.
Storm T, Thamsborg G, Steinische T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in postmenopausal osteoporosis. N Engl J Med 1990;322:1265–71.
Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licita AA, Chesnut CH III. Four year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95:557–67.
Jönsson B, Christiansen C, Johnell O, Hedbrandt J. The cost-effectiveness of fracture prevention in established osteoporosis. Osteoporosis Int 1995;5:136–42.
Tosteson AN, Rosenthal DI, Melton J, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990;113:594–603.
Sernbo I, Johnell O. Consequences of a hip fracture: a prospective study over 1 year. Osteoporosis Int 1993;3:148–53.
Office of Technology Assessment (OTA). Hip fracture outcomes in people age fifty and over. Washington, DC: OTA, 1994.